U.S. Markets open in 9 hrs 18 mins
  • S&P Futures

    3,794.00
    +3.50 (+0.09%)
     
  • Dow Futures

    30,799.00
    -29.00 (-0.09%)
     
  • Nasdaq Futures

    13,031.00
    +45.50 (+0.35%)
     
  • Russell 2000 Futures

    2,140.00
    -7.30 (-0.34%)
     
  • Crude Oil

    53.35
    +0.37 (+0.70%)
     
  • Gold

    1,849.40
    +9.20 (+0.50%)
     
  • Silver

    25.50
    +0.18 (+0.71%)
     
  • EUR/USD

    1.2151
    +0.0018 (+0.1458%)
     
  • 10-Yr Bond

    1.0920
    -0.0050 (-0.46%)
     
  • Vix

    23.24
    -1.10 (-4.52%)
     
  • GBP/USD

    1.3652
    +0.0017 (+0.1270%)
     
  • USD/JPY

    103.7500
    -0.1420 (-0.1367%)
     
  • BTC-USD

    35,396.12
    -498.13 (-1.39%)
     
  • CMC Crypto 200

    702.62
    -12.58 (-1.76%)
     
  • FTSE 100

    6,712.95
    -7.70 (-0.11%)
     
  • Nikkei 225

    28,481.59
    -151.91 (-0.53%)
     

LAWSUITS FILED AGAINST BRY, NAK and NERV - Jakubowitz Law Pursues Shareholders Claims

·3 min read

NEW YORK, NY / ACCESSWIRE / December 29, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Berry Corporation (NASDAQ:BRY)

CONTACT JAKUBOWITZ ABOUT BRY:
https://claimyourloss.com/securities/berry-corporation-loss-submission-form/?id=11850&from=1

Lawsuit on behalf of investors who purchased: (a) Berry common stock pursuant and/or traceable to the Company's initial public offering conducted on or about July 26, 2018; or (b) Berry securities between July 26, 2018 and November 3, 2020, both dates inclusive

Lead Plaintiff Deadline: January 21, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Berry had materially overstated its operational efficiency and stability; (ii) Berry's operational inefficiency and instability would foreseeably necessitate operational improvements that would disrupt the Company's productivity and increase costs; (iii) the foregoing would foreseeably negatively impact the Company's revenues; and (iv) as a result, the Offering Documents and the Company's public statements were materially false and/or misleading and failed to state information required to be stated therein.

Northern Dynasty Minerals Ltd. (NYSE:NAK)

CONTACT JAKUBOWITZ ABOUT NAK:
https://claimyourloss.com/securities/northern-dynasty-minerals-ltd-loss-submission-form/?id=11850&from=1

Class Period: December 21, 2017 - November 25, 2020

Lead Plaintiff Deadline: February 2, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's Pebble Project was contrary to Clean Water Act guidelines and to the public interest; (2) the Company planned that the Pebble Project would be larger in duration and scope than conveyed to the public; (3) as a result, the Company's permit applications for the Pebble Project would be denied by the U.S. Army Corps of Engineers; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Minerva Neurosciences, Inc. (NASDAQ:NERV)

CONTACT JAKUBOWITZ ABOUT NERV:
https://claimyourloss.com/securities/minerva-neurosciences-inc-loss-submission-form/?id=11850&from=1

Class Period: May 15, 2017 - November 30, 2020

Lead Plaintiff Deadline: February 8, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the truth about the feedback received from the FDA concerning the "end-of-Phase 2" meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be "highly unlikely" to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to "substantial review issues" because the trials were inadequate and not well-controlled; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law



View source version on accesswire.com:
https://www.accesswire.com/622571/LAWSUITS-FILED-AGAINST-BRY-NAK-and-NERV--Jakubowitz-Law-Pursues-Shareholders-Claims